Heart failure & cardiomyopathiesRandomised controlled trial
N-Terminal Pro-B-Type Natriuretic Peptide Post-Discharge Monitoring in the Management of Patients with Heart Failure and Preserved Ejection Fraction – A Randomized Trial: The NICE Study
- Randomised controlled trial
- multicentre
- open-label
- event blinding
Authors' conclusion
Post-discharge monitoring of NT-proBNP in HFpEF patients did not exhibit an association with reduced rates of HF hospitalization in this study.
Study context
- Population
- Patients admitted with HFpEF (LVEF >50%), after discharge
- Participants
- 157 patients
- Comparison
- NT-proBNP monitoring vs no access to NT-proBNP
- NT-proBNP monitoringn = 79
- Controln = 78reference
- Primary endpoint
- Heart failure (HF) rehospitalizations
- Follow-up
- 6 months
Primary result
As reported in the abstract
Hazard ratio
1.15
95% CI 0.47–2.81
P = 0.760
By group
NT-proBNP monitoring vs Control
HR 1.15 (95% CI 0.47–2.81); P = 0.760
Secondary outcomes
| Outcome | NT-proBNP monitoring | Control | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Death | 1.3% | 10.1% | 0.12 (0.02–0.98) | P = 0.048 | |
| 0.050.21520Hazard ratio (log scale) |
Any adverse clinical event
P = 0.17
| Outcome | NT-proBNP monitoring | Control | Estimate | P value |
|---|---|---|---|---|
| Non-HF hospitalizations | Not reported in the abstract | 19.0% | P = 0.171 |
Medical therapy
- Higher doses of diuretics and renin-angiotensin system inhibitors (ACEi/ARB) with NT-proBNP monitoring
Original publication
N-Terminal Pro-B-Type Natriuretic Peptide Post-Discharge Monitoring in the Management of Patients with Heart Failure and Preserved Ejection Fraction – A Randomized Trial: The NICE Study. Eur J Heart Fail. Published 12 April 2024. doi:10.1002/ejhf.3222
Summarised from the published abstract; every number is checked against it